These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 35778272)
1. Possible future avenues for myositis therapeutics: DM, IMNM and IBM. Connolly CM; Plomp L; Paik JJ; Allenbach Y Best Pract Res Clin Rheumatol; 2022 Jun; 36(2):101762. PubMed ID: 35778272 [TBL] [Abstract][Full Text] [Related]
2. Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review. Kamperman RG; van der Kooi AJ; de Visser M; Aronica E; Raaphorst J Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457124 [TBL] [Abstract][Full Text] [Related]
3. [Idiopathic inflammatory myopathies. A review]. Acosta I; Matamala JM; Jara P; Pino F; Gallardo A; Verdugo R Rev Med Chil; 2019 Mar; 147(3):342-355. PubMed ID: 31344172 [TBL] [Abstract][Full Text] [Related]
9. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use. Gandiga PC; Ghetie D; Anderson E; Aggrawal R Curr Rheumatol Rep; 2023 Aug; 25(8):152-168. PubMed ID: 37261663 [TBL] [Abstract][Full Text] [Related]
10. Inflammatory muscle disease - An update. Baig S; Paik JJ Best Pract Res Clin Rheumatol; 2020 Feb; 34(1):101484. PubMed ID: 32046904 [TBL] [Abstract][Full Text] [Related]
11. Contribution of Complement, Microangiopathy and Inflammation in Idiopathic Inflammatory Myopathies. Honda M; Shimizu F; Sato R; Nakamori M J Neuromuscul Dis; 2024; 11(1):5-16. PubMed ID: 38143369 [TBL] [Abstract][Full Text] [Related]
12. What is New in Idiopathic Inflammatory Myopathies: Mechanisms and Therapies. Khadilkar SV; Dhamne MC Ann Indian Acad Neurol; 2020; 23(4):458-467. PubMed ID: 33223661 [TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase 4/CD26 expression in human idiopathic inflammatory myopathies reveals skeletal muscle injury and vascular inflammation. De Lorenzo R; Monno A; Sciorati C; Lorenzetti I; Cavalli S; Bonomi F; Previtali SC; Rovere-Querini P Clin Exp Rheumatol; 2022 Feb; 40(2):237-246. PubMed ID: 34796850 [TBL] [Abstract][Full Text] [Related]
14. Where are we moving in the classification of idiopathic inflammatory myopathies? Tanboon J; Uruha A; Stenzel W; Nishino I Curr Opin Neurol; 2020 Oct; 33(5):590-603. PubMed ID: 32852298 [TBL] [Abstract][Full Text] [Related]
18. Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management. Basharat P; Christopher-Stine L Curr Rheumatol Rep; 2015 Dec; 17(12):72. PubMed ID: 26515574 [TBL] [Abstract][Full Text] [Related]
19. Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy. Lia A; Annese T; Fornaro M; Giannini M; D'Abbicco D; Errede M; Lorusso L; Amati A; Tampoia M; Trojano M; Virgintino D; Ribatti D; Serlenga L; Iannone F; Girolamo F Rheumatology (Oxford); 2022 Aug; 61(8):3448-3460. PubMed ID: 34864921 [TBL] [Abstract][Full Text] [Related]
20. The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review. Gasparotto M; Franco C; Zanatta E; Ghirardello A; Zen M; Iaccarino L; Fabris B; Doria A; Gatto M Autoimmun Rev; 2023 Jun; 22(6):103334. PubMed ID: 37068699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]